Recent News

Our most critical insights will come years after treatment ends, as long-term follow-up is essential to understanding lasting effects and benefits.

Learn about the importance of the Primary Completion Date, an exciting alternative to MRIs for prostate cancer biopsies, and more.  …

COMPPARE Principal Investigator Nancy Price Mendenhall, MD, FACR, FASTRO, was invited to speak at the sixth annual Biennial Science of Global Prostate Cancer Disparities in Black Men Conference, held virtually November 10-13, 2021. The Prostate Cancer Transatlantic Consortium launched the event in Jacksonville, FL in 2010. Funded by the National…

The latest edition of the COMPPARE CONNECTION is now online.

Dr. Nancy Mendenhall, COMPPARE Principal Investigator, and Charles Griggs, Minority Engagement Group Coordinator, have been invited to participate in the seventh annual meeting of the Patient-Centered Outcomes Research Institute (PCORI), to be held virtually in November. Dr. Mendenhall and Mr. Griggs will contribute as panelists in a session focused on…

On February 17, 2021, Cancer Connections, a UF Monthly Educational & Networking Meeting, presented “COMPPARE Clinical Trial: Protons vs Photons to Treat Prostate Cancer.” Dr. Nancy Mendenhall, M.D., FACR, FASTRO, COMPPARE Principal Investigator, provided an overview of the UF-led national ongoing prostate cancer clinical trial, highlighting the differences between between…

The COMPPARE team was pleased to announce on November 13, 2020 that the study had enrolled 1,000 patients, one-third of its 3,000-patient goal. COMPPARE’s partner site, the James M. Slater, MD Proton Treatment & Research Center, Loma Linda, CA, enrolled the 1,000th patient. COMPPARE stands for “A Prospective COMparative Study…

Mr. Charles Griggs and Drs. Nancy Mendenhall and Curtiland Deville participated in “Our Health, Our Voice: Improving Prostate Cancer Outcomes through Participation in Research” on Wednesday, November 4, 2020. The live information session, presented by 100 Black Men of America, Inc., a COMPPARE partner organization, focused on the…

If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist. Approximately one…

The 2020 COMPPARE Workshop: Accrual, Monitoring, and Engagement, held in Amelia Island, FL, January 17 – 19, 2020, allowed researchers and patients to cross-pollinate their ideas and help COMPPARE succeed. One important outcome of the meeting, the decision to expand COMPPARE eligibility criteria, was derived from…